Terevalefim

DB16397InvestigationalSmall molecule

Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

Mechanism: Terevalefim, a small molecule developed by Angion Biomedica Corp., mimics the activity of hepatocyte growth factor (HGF). Through its actions, it activates the c-Met cascade, exhibits c-Met dependence and c-Met receptor activation. As it is able to activate repair pathways, it has been tested in clinical trials for acute kidney injury and in delayed graft function. As of July 2020, Angion has announced a Phase 2 proof-of-concept trial to invesigate terevalefim on preventing and mitigating lung injury in patients with COVID-19 (NCT04459676).
Curator reviewed
Formula / weight: C₉H₈N₂S · 176.24 g/mol (avg)
Also known as: Refanalin
Code names: ANG-3777 · SNV-003

Resolves to

Compound

Structure

InChIKeyFOHWAQGURRYJFK-ONEGZZNKSA-NSMILESN1C=CC(\C=C\C2=CC=CS2)=N1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Terevalefim, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.